The use of progesterone preparations during embryo transfer in IVF programs is a necessary step in the successful treatment of infertility. According to the results of a systematic review published in 2015, the use of progesterone preparations in IVF programs significantly increases the pregnancy rate compared with placebo. Most specialists in the world prefer the vaginal route of administration of progesterone (74.1% of respondents).

OBJECTIVE

Analysis of the effectiveness of IVF programs with embryo transfer in patients with support for the luteal phase of the cycle with bioadhesive vaginal progesterone gel (Miragel) and micronized progesterone capsules (Utrogestan) in terms of clinical pregnancy rate per embryo transfer

MATERIAL AND METHODS

A retrospective comparative analysis of the effectiveness of IVF in terms of the frequency of clinical pregnancy in terms of embryo transfer in two groups of patients using different forms of progesterone for hormonal support of the luteal phase (LF) was carried out. The study included 309 blind patients divided into two groups. Patients of the first group (n=154) were observed as a hormonal support for LF for 24 hours after follicle puncture, vaginal progesterone gel 90 mg/day (Miragel, VERTEX JSC, Russia) was administered, patients of the second group (n=155) were observed from the day of admission after follicle puncture micronized progesterone 200 mg 3 times a day vaginally (Utrogestan, BESINS HEALTHCARE). Patients were reviewed according to clinical characteristics. All patients underwent a protocol with GnRH antagonists, rFSH stimulation, rhCG was called as a trigger, embryo cultivation was carried out in the Embryoscope incubator, on the 5th day after the puncture, stage 1 embryo transfer was carried out 3—4 according to Gartner’s secretions and a KID SCORE of at least 7 points.

RESULTS

The frequency of clinical pregnancy in the calculation of embryo transfer in the first group is 59.1%, in the second group — 55.2% and the indicator of differences between pregnancies is not taken into account (p=0.49).

CONCLUSION

Evaluation of the effectiveness of the use of two vaginal progesterone preparations (Miragel bioadhesive gel and Utrogestan capsules) in IVF programs showed high efficiency of both drugs in terms of pregnancy rate per embryo transfer. At the same time, compliance with Miragel was higher due to a more convenient form of application and the need for a single administration of the drug per day.